0001880794-21-000003.txt : 20211217 0001880794-21-000003.hdr.sgml : 20211217 20211216180813 ACCESSION NUMBER: 0001880794-21-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211217 DATE AS OF CHANGE: 20211216 EFFECTIVENESS DATE: 20211217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Attivare Therapeutics, Inc. CENTRAL INDEX KEY: 0001880794 IRS NUMBER: 861598751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-412051 FILM NUMBER: 211498986 BUSINESS ADDRESS: STREET 1: 22 STRATHMORE ROAD CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 857-675-1592 MAIL ADDRESS: STREET 1: 22 STRATHMORE ROAD CITY: NATICK STATE: MA ZIP: 01760 D/A 1 primary_doc.xml X0708 D/A LIVE 0001880794 Attivare Therapeutics, Inc. 22 STRATHMORE ROAD NATICK MA MASSACHUSETTS 01760 857-675-1592 DELAWARE None None Corporation true 2020 Edward Doherty c/o Attivare Therapeutics, Inc. 22 Strathmore Natick MA MASSACHUSETTS 01760 Executive Officer Jessica McDonough c/o Attivare Therapeutics, Inc. 22 Strathmore Natick MA MASSACHUSETTS 01760 Director Zeshan Muhammedi c/o Attivare Therapeutics, Inc. 22 Strathmore Natick MA MASSACHUSETTS 01760 Director Joaquim Trias c/o Attivare Therapeutics, Inc. 22 Strathmore Natick MA MASSACHUSETTS 01760 Executive Officer Director Other Decline to Disclose 06b true 0001880794-21-000001 2021-08-16 false true true Amount sold includes the conversion of debt and the securities issuable upon conversion. false 0 7827325 5876955 1950370 The amount sold includes convertible debt and the securities issuable upon conversion. false 23 0 0 0 false Attivare Therapeutics, Inc. /s/ Joaquim Trias Joaquim Trias Chief Executive Officer 2021-12-16